RUN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sunrun Inc is not a strong buy for a beginner investor with a long-term focus at this time. The stock faces significant challenges, including negative analyst sentiment, a declining financial performance, and ongoing structural issues in the residential solar market. While there are some positive catalysts, such as hedge fund interest and improved gross margins, these are outweighed by the negative factors. It is advisable to hold off on investing until clearer signs of recovery or stability emerge.
The technical indicators show mixed signals. The MACD is positively contracting and above zero, suggesting some bullish momentum. However, the RSI is neutral at 42.629, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 12.137), with resistance at R1: 13.352.
Hedge fund PlusTick Management recently acquired 500,000 shares, reflecting confidence in the company.
Gross margin increased significantly YoY, showing operational improvements.
Revenue grew by 123.50% YoY in Q4 2025.
Analysts have overwhelmingly lowered price targets, with some predicting significant downside.
The company is under investigation for possible securities fraud, following a 35.11% stock price drop after its Q4 report.
Net income and EPS dropped significantly YoY, indicating poor profitability.
The residential solar market is undergoing structural challenges, with Sunrun predicted to struggle in surviving the shakeout.
In Q4 2025, revenue increased by 123.50% YoY to $1.16 billion. However, net income dropped by -103.68% YoY to $103.57 million, and EPS declined by -103.01% YoY to $0.38. Gross margin improved to 37.57%, up 99.84% YoY, but overall profitability remains a concern.
Analysts have a predominantly negative outlook on Sunrun. GLJ Research has a Sell rating with a price target of $4.63, implying a 63% downside. Morgan Stanley and Freedom Capital have downgraded their ratings, citing concerns about solar origination growth and valuation. UBS and Oppenheimer maintain Buy/Outperform ratings but have lowered price targets, reflecting cautious optimism.
